Literature DB >> 18630507

Up-regulation of survivin mRNA might be a marker for non-invasive detection of non-small cell lung cancer rather than for prognosis.

Ute Warnecke-Eberz1, Stephan E Baldus, Elfriede Bollschweiler, Arnulf H Hoelscher, Ralf Metzger.   

Abstract

BACKGROUND: Survivin suppresses programmed cell death and regulates cell division. To evaluate the prognostic importance of the apoptosis inhibitor survivin for non-small cell lung cancer (NSCLC), a study was performed in 64 patients with R0 resections for NSCLC and histopathological stages I-IIIA. PATIENTS AND METHODS: Analysis of survivin mRNA expression was performed on 64 paired tumor and normal tissues by quantitative real-time RT-PCR.
RESULTS: Survivin expression in tumors (median 3.68, min. 0.19, max. 28.63) was significantly higher (p < 0.04) than in corresponding normal tissues (median 1.68, min. 0.03, max. 155.59). Survivin mRNA was up-regulated in tumors of 42 patients (66%). However, survivin overexpression did not correlate with survival of lung cancer patients. There was no significant association of survivin mRNA levels with histological type (p = 0.29), pT (p = 0.41) and pN categories (p = 0.57), grading of the primary tumor (p = 0.45), or histopathological stage (p = 0.87).
CONCLUSION: Overexpression of survivin mRNA in NSCLC might be a marker for noninvasive tumor detection, but has no prognostic importance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18630507

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies.

Authors:  Li-Nian Huang; Dong-Sheng Wang; Yu-Qing Chen; Cheng-Ling Zhao; Bei-Lei Gong; An-Bang Jiang; Wei Jia; Feng-Dan Hu
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

2.  Beyond pancreatic carcinoma: The close relationship between survivin levels and prognosis in systemic malignancies.

Authors:  Shailendra Kapoor
Journal:  World J Clin Oncol       Date:  2012-05-10

Review 3.  MicroRNA binding site polymorphisms as biomarkers in cancer management and research.

Authors:  Monica Cipollini; Stefano Landi; Federica Gemignani
Journal:  Pharmgenomics Pers Med       Date:  2014-07-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.